Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
8 p, 1.6 MB Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer : a subgroup analysis from the phase 3 TAGS study / Mansoor, Wasat (The Christie NHS Foundation Trust) ; Arkenau, Hendrik-Tobias (University College London) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Shitara, Kohei (National Cancer Center Hospital East) ; Thuss-Patience, Peter (Charité - Universitätsmedizin Berlin) ; Cuffe, Sinead (St. James's Hospital ( Dublín, Irlanda)) ; Dvorkin, Mikhail (Omsk Regional Clinical Centre of Oncology) ; Park, David (St, Joseph Heritage Healthcare) ; Ando, Takayuki (University of Toyama) ; Van Den Eynde, Marc (UCL Cliniques Universitaires Saint-Luc) ; Beretta, Giordano D. (Humanitas Gavazzeni) ; Zaniboni, Alberto (Fondazione Poliambulanza-Istituto Ospedaliero) ; Doi, Toshihiko (National Cancer Center Hospital East) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Ilson, David H. (Memorial Sloan Kettering Cancer Center) ; Makris, Lukas (Stathmi, Inc, New Hope, PA USA) ; Benhadji, Karim A. (Taiho Oncology) ; Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Universitat Autònoma de Barcelona
Patients with advanced gastroesophageal junction cancer (GEJC) have poor survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers (GCs) as a whole are lacking. Trifluridine/tipiracil (FTD/TPI) was approved for previously treated metastatic GC or GEJC (mGC/mGEJC) based on results of the phase 3 TAGS trial. [...]
2021 - 10.1007/s10120-021-01156-x
Gastric Cancer, Vol. 24 (march 2021) , p. 970-977  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.